Kaissan (Clopidogrel Hydrochloride)

Clopidogrel Hydrochloride, the active ingredient in Kaissan, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It reduces the risk of clot formation and is indicated for patients with acute coronary syndrome, prior myocardial infarction, stroke, or peripheral arterial disease. It is used in secondary prevention after myocardial infarction and in patients with established atherosclerotic disease.

GNH USA supplies Kaissan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Clopidogrel Hydrochloride is an antiplatelet agent that inhibits platelet aggregation in arterial thrombosis. - Acute coronary syndrome: reduces risk of recurrent cardiovascular events. - Post‑myocardial infarction secondary prevention: lowers incidence of new heart attacks. - Stroke prevention: decreases likelihood of recurrent ischemic stroke or transient ischemic attack. - Peripheral arterial disease: diminishes limb‑related ischemic events and need for revascularisation.

Clopidogrel Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate headache reported. - Nausea: occasional feeling of nausea or upset stomach. - Diarrhoea: loose stools occurring in some patients. - Rash: mild skin irritation or rash.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Thrombocytopenia: marked reduction in platelet count. - Hypersensitivity reactions: including angioedema, urticaria, or anaphylaxis.

When prescribing Clopidogrel Hydrochloride, consider the following precautions. - Assess bleeding risk: evaluate patient history for active or recent bleeding. - Monitor platelet count: periodic checks recommended during therapy. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid concomitant NSAIDs or anticoagulants unless clinically necessary. - Discontinue before surgery: stop therapy as advised by the surgical team. - Store at ambient temperature: keep in the original pack, protect from moisture.

Clopidogrel Hydrochloride interacts with several drug classes.

Major Interactions (Avoid): - Proton pump inhibitors (e.g., omeprazole): may reduce antiplatelet effect. - Anticoagulants (e.g., warfarin): increase risk of serious bleeding. - NSAIDs (e.g., ibuprofen): heighten bleeding tendency.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may lower activation of clopidogrel. - CYP3A4 inhibitors (e.g., ketoconazole): can increase plasma levels. - Other antiplatelet agents (e.g., aspirin): monitor for additive bleeding risk.